STRUCTURE THERAPEUTICS INC (GPCR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.36+0.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GPCR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -50.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GPCR — litigation filed
Dated 2026-09-08
Other Events. ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results On September 8, 2026, the Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial. The SAD portion evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamic (PD) effects of ACCG-2671 in 31 healthy adult participants without obe…
Why it matters: The single-dose trial showed weight loss, but it did not test repeated dosing in people with obesity. The next study tests safety and dose over 12 weeks.
Watch forThe 12-week study reports weight loss with no serious safety issue and no treatment stoppage due to side effects.
Also watch forThe study reports a serious safety issue or treatment stops due to side effects. Or, the readout is later than 1H 2027.
Why it matters: These two trials test aleniglipron in large groups and are meant to support global drug filings. Slow enrollment could delay the planned 2H 2028 results.
Watch forCompany updates show ongoing enrollment in both trials, with topline results still planned for 2H 2028.
Also watch forThe company reports a pause, slow enrollment, or a delay to the 2H 2028 topline window.
Why it matters: Animal data showed more weight loss with the two drugs than with either drug alone. A human trial will test whether that result carries over.
Supportive ifThe company reports first-patient dosing in the combination trial by the end of Q4 2026.
Worry ifThe combination trial has not started by year-end 2026, or the company reports a delay.
Why it matters: Starting this trial would move a second oral amylin drug into human testing. A delay would slow that part of the drug pipeline.
Supportive ifThe company reports that the first participants received ACCG-3535 in its Phase 1 trial by the end of Q4 2026.
Worry ifNo first-patient dosing is reported by year-end 2026, or the company delays the trial start.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$213 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $690 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,830 loss on $10,000 · 78.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This study tests whether people can move from an injected GLP-1 drug to daily oral aleniglipron. A clear result could support its use for weight maintenance.
Watch forQ4 2026 results show participants kept most of their weight loss after switching to aleniglipron for 12 weeks.
Also watch forQ4 2026 results show that participants regained weight. Or, the data readout is later than the stated window.